Candesartan induces a prolonged proangiogenic effect and augments endothelium-mediated neuroprotection after oxygen and glucose deprivation: Role of vascular endothelial growth factors A and B

Journal of Pharmacology and Experimental Therapeutics

Volumn 349, Issue 3, 2014, Pages 444-457

  Soliman, Sahar ^a,b   Ishrat, Tauheed ^a,b   Pillai, Anilkumar ^c   Somanath, Payaningal R ^a,b,c   Ergul, Adviye ^a,b,c   El Remessy, Azza B ^a,b,c   Fagan, Susan C ^a,b,c  

^a UNIVERSITY OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; CANDESARTAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN A; VASCULOTROPIN B;

ADULT; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN HOMOGENATE; BRAIN ISCHEMIA; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYPOGLYCEMIA; HYPOXIA; MALE; NEUROPROTECTION; NITRATIVE STRESS; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; RAT; RECEPTOR UPREGULATION; SINGLE DRUG DOSE; WESTERN BLOTTING;

ANGIOPOIETIN-1; ANIMALS; BENZIMIDAZOLES; CELL CULTURE TECHNIQUES; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GLUCOSE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; NEUROPROTECTIVE AGENTS; OXYGEN; RATS; RATS, WISTAR; STROKE; TETRAZOLES; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR B;

EID: 84901236192     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.212613     Document Type: Article

References (60)

1. Abdelsaid MA, Pillai BA, Matragoon S, Prakash R, Al-Shabrawey M, and El-Remessy AB (2010) Early intervention of tyrosine nitration prevents vaso-obliteration and neovascularization in ischemic retinopathy. J Pharmacol Exp Ther 332:125-134.
2. Alhusban A, Kozak A, Ergul A, and Fagan SC (2013) AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. J Pharmacol Exp Ther 344: 348-359.
3. Beck H and Plate KH (2009) Angiogenesis after cerebral ischemia. Acta Neuropathol 117:481-496.
4. Bhardwaj S, Roy H, Gruchala M, Viita H, Kholova I, Kokina I, Achen MG, Stacker SA, Hedman M, and Alitalo K, et al. (2003) Angiogenic responses of vascular en-dothelial growth factors in periadventitial tissue. Hum Gene Ther 14:1451-1462.
5. Cao L, Jiao X, Zuzga DS, Liu Y, Fong DM, Young D, and During MJ (2004) VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 36:827-835.
6. Chen J, Zhang C, Jiang H, Li Y, Zhang L, Robin A, Katakowski M, Lu M, and Chopp M (2005) Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab 25:281-290.
7. Dassan P, Brown MM, Gregoire SM, Keir G, and Werring DJ (2012) Association of cerebral microbleeds in acute ischemic stroke with high serum levels of vascular endothelial growth factor. Arch Neurol 69:1186-1189.
8. Davis S and Yancopoulos GD (1999) The angiopoietins: Yin and Yang in angiogen-esis. Curr Top Microbiol Immunol 237:173-185.
9. El-Remessy A, Shanab A, Matragoon S, and Fagan S and Retinopathy (2013) Vascular protective effects of candesartan in ischemic retinopathy (Abstract). Invest Ophthalmol Vis Sci 54:4538.
10. el-Remessy AB, Bartoli M, Platt DH, Fulton D, and Caldwell RB (2005) Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration. J Cell Sci 118:243-252.
11. Engelhorn T, Goerike S, Doerfler A, Okorn C, Forsting M, Heusch G, and Schulz R (2004) The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 24:467-474.
12. Ferrara N (1995) The role of vascular endothelial growth factor in pathological an-giogenesis. Breast Cancer Res Treat 36:127-137.
13. Forder JP, Munzenmaier DH, and Greene AS (2005) Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat. Am J Physiol Heart Circ Physiol 288:H1989-H1996.
14. Gigante B, Rubattu S, Russo R, Porcellini A, Enea I, De Paolis P, Savoia C, Natale A, Piras O, and Volpe M (1997) Opposite feedback control of renin and aldosterone biosynthesis in the adrenal cortex by angiotensin II AT1-subtype receptors. Hypertension 30:563-568.
15. Guan W, Kozak A, El-Remessy AB, Johnson MH, Pillai BA, and Fagan SC (2011a) Acute treatment with candesartan reduces early injury after permanent middle cerebral artery occlusion. Transl Stroke Res 2:179-185.
16. Guan W, Kozak A, and Fagan SC (2011b) Drug repurposing for vascular protection after acute ischemic stroke. Acta Neurochir Suppl (Wien) 111:295-298.
17. Guan W, Somanath PR, Kozak A, Goc A, El-Remessy AB, Ergul A, Johnson MH, Alhusban A, Soliman S, and Fagan SC (2011c) Vascular protection by angiotensin receptor antagonism involves differential VEGF expression in both hemispheres after experimental stroke. PLoS ONE 6:e24551.
18. Guo S, Kim WJ, Lok J, Lee SR, Besancon E, Luo BH, Stins MF, Wang X, Dedhar S, and Lo EH (2008) Neuroprotection via matrix-trophic coupling between cerebral endothelial cells and neurons. Proc Natl Acad Sci USA 105:7582-7587.
19. Hosomi N, Nishiyama A, Ban CR, Naya T, Takahashi T, Kohno M, and Koziol JA (2005) Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 134:225-231.
20. Huang LE, Arany Z, Livingston DM, and Bunn HF (1996) Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271:32253-32259.
21. Ishikawa H, Tajiri N, Shinozuka K, Vasconcellos J, Kaneko Y, Lee HJ, Mimura O, Dezawa M, Kim SU, and Borlongan CV (2013) Vasculogenesis in experimental stroke after human cerebral endothelial cell transplantation. Stroke 44:3473-3481.
22. Ishrat T, Pillai B, Ergul A, Hafez S, and Fagan SC (2013) Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke. Neurochem Res 38:2668-2677.
23. Jin K, Zhu Y, Sun Y, Mao XO, Xie L, and Greenberg DA (2002) Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA 99:11946-11950.
24. Jin KL, Mao XO, and Greenberg DA (2000) Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA 97: 10242-10247.
25. Kochuparambil ST, Al-Husein B, Goc A, Soliman S, and Somanath PR (2011) Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther 336:496-505.
26. Kozak A, Ergul A, El-Remessy AB, Johnson MH, Machado LS, Elewa HF, Abdelsaid M, Wiley DC, and Fagan SC (2009) Candesartan augments ischemia-induced proangio-genic state and results in sustained improvement after stroke. Stroke 40:1870-1876.
27. Kozak W, Kozak A, Johnson MH, Elewa HF, and Fagan SC (2008) Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. J Pharmacol Exp Ther 326:773-782.
28. Krupinski J, Kaluza J, Kumar P, Kumar S, and Wang JM (1994) Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 25:1794-1798.
29. Levy AP, Levy NS, Wegner S, and Goldberg MA (1995) Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270: 13333-13340.
30. Li JM, Mogi M, Iwanami J, Min LJ, Tsukuda K, Sakata A, Fujita T, Iwai M, and Horiuchi M (2008a) Temporary pretreatment with the angiotensin II type 1 receptor blocker, valsartan, prevents ischemic brain damage through an increase in capillary density. Stroke 39:2029-2036.
31. Li Q, Ford MC, Lavik EB, and Madri JA (2006) Modeling the neurovascular niche: VEGF-And BDNF-mediated cross-talk between neural stem cells and endothelial cells: an in vitro study. J Neurosci Res 84:1656-1668.
32. Li X, Lee C, Tang Z, Zhang F, Arjunan P, Li Y, Hou X, Kumar A, and Dong L (2009) VEGF-B: a survival, or an angiogenic factor? Cell Adhes Migr 3:322-327.
33. Li Y, Zhang F, Nagai N, Tang Z, Zhang S, Scotney P, Lennartsson J, Zhu C, Qu Y, and Fang C, et al. (2008b) VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest 118:913-923.
34. Manoonkitiwongsa PS, Jackson-Friedman C, McMillan PJ, Schultz RL, and Lyden PD (2001) Angiogenesis after stroke is correlated with increased numbers of macrophages: the clean-up hypothesis. J Cereb Blood Flow Metab 21:1223-1231.
35. Matsuzaki H, Tamatani M, Yamaguchi A, Namikawa K, Kiyama H, Vitek MP, Mitsuda N, and Tohyama M (2001) Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades. FASEB J 15:1218-1220.
36. Mould AW, Greco SA, Cahill MM, Tonks ID, Bellomo D, Patterson C, Zournazi A, Nash A, Scotney P, and Hayward NK, et al. (2005) Transgenic overexpression of vascular endothelial growth factor-B isoforms by endothelial cells potentiates postnatal vessel growth in vivo and in vitro. Circ Res 97:e60-e70.
37. Munzenmaier DH and Greene AS (2006) Chronic angiotensin II AT1 receptor blockade increases cerebral cortical microvessel density. Am J Physiol Heart Circ Physiol 290:H512-H516.
38. Navaratna D, Guo S, Arai K, and Lo EH (2009) Mechanisms and targets for angio-genic therapy after stroke. Cell Adhes Migr 3:216-223.
39. Paxinos G and Franklin KBJ (2001) The Mouse Brain in Stereotaxic Coordinates, Academic Press, San Diego.
40. Pillai A, Dhandapani KM, Pillai BA, Terry AV, Jr, and Mahadik SP (2008) Eryth-ropoietin prevents haloperidol treatment-induced neuronal apoptosis through regulation of BDNF. Neuropsychopharmacology 33:1942-1951.
41. Rissanen TT, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI, Kholová I, Kauppinen RA, Achen MG, and Stacker SA, et al. (2003) VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 92:1098-1106.
42. Schulz M and Schmoldt A (2003) Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 58:447-474.
43. Shibuya M (2013) Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 153:13-19.
44. Silvestre JS, Tamarat R, Ebrahimian TG, Le-Roux A, Clergue M, Emmanuel F, Duriez M, Schwartz B, Branellec D, and Lévy BI (2003) Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res 93:114-123.
45. Sun Y, Jin K, Childs JT, Xie L, Mao XO, and Greenberg DA (2006) Vascular endo-thelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration. Dev Biol 289:329-335.
46. Tao Z, Chen B, Tan X, Zhao Y, Wang L, Zhu T, Cao K, Yang Z, Kan YW, and Su H (2011) Coexpression of VEGF and angiopoietin-1 promotes angiogenesis and car-diomyocyte proliferation reduces apoptosis in porcine myocardial infarction (MI) heart. Proc Natl Acad Sci USA 108:2064-2069.
47. Teng H, Zhang ZG, Wang L, Zhang RL, Zhang L, Morris D, Gregg SR, Wu Z, Jiang A, and Lu M, et al. (2008) Coupling of angiogenesis and neurogenesis in cultured endothelial cells and neural progenitor cells after stroke. J Cereb Blood Flow Metab 28:764-771.
48. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, and Yancopoulos GD (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6:460-463.
49. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, and McDonald DM (1999) Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286:2511-2514.
50. Valable S, Montaner J, Bellail A, Berezowski V, Brillault J, Cecchelli R, Divoux D, Mackenzie ET, Bernaudin M, and Roussel S, et al. (2005) VEGF-induced BBB permeability is associated with an MMP-9 activity increase in cerebral ischemia: both effects decreased by Ang-1. J Cereb Blood Flow Metab 25:1491-1504.
51. 2-regulated gene expression. FASEB J 16:1151-1162.
52. Willis LM, El-Remessy AB, Somanath PR, Deremer DL, and Fagan SC (2011) An-giotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin Sci (Lond) 120:307-319.
53. Wright CE (2002) Effects of vascular endothelial growth factor (VEGF)A and VEGFB gene transfer on vascular reserve in a conscious rabbit hindlimb ischaemia model. Clin Exp Pharmacol Physiol 29:1035-1039.
54. Xie L, Mao X, Jin K, and Greenberg DA (2013) Vascular endothelial growth factor-B expression in postischemic rat brain. Vasc Cell 5:8.
55. Xiong Y, Mahmood A, and Chopp M (2010) Angiogenesis, neurogenesis and brain recovery of function following injury. Curr Opin Investig Drugs 11:298-308.
56. Youn SW, Lee SW, Lee J, Jeong HK, Suh JW, Yoon CH, Kang HJ, Kim HZ, Koh GY, and Oh BH, et al. (2011) COMP-Ang1 stimulates HIF-1a-mediated SDF-1 over-expression and recovers ischemic injury through BM-derived progenitor cell recruitment. Blood 117:4376-4386.
57. Zhang F, Tang Z, Hou X, Lennartsson J, Li Y, Koch AW, Scotney P, Lee C, Arjunan P, and Dong L, et al. (2009) VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 106:6152-6157.
58. Zhang Z and Chopp M (2002) Vascular endothelial growth factor and angiopoietins in focal cerebral ischemia. Trends Cardiovasc Med 12:62-66.
59. Zhang ZG, Zhang L, Croll SD, and Chopp M (2002) Angiopoietin-1 reduces cerebral blood vessel leakage and ischemic lesion volume after focal cerebral embolic ischemia in mice. Neuroscience 113:683-687.
60. Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, van Bruggen N, and Chopp M (2000) VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest 106:829-838.